Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 11/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.43 |
| ▸ | PYGM | P11217 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834970 | 0.92 | TK2 (0.47) | TK2P2RY2PYGM | |
| SCHEMBL19834969 | 0.92 | TK2 (0.45) | TK2P2RY2PYGM | |
| SCHEMBL10101281 | 0.90 | TK2 (0.53) | TK2PYGM | |
| SCHEMBL29163657 | 0.90 | TK2 (0.53) | TK2PYGM | |
| SCHEMBL10104844 | 0.90 | TK2 (0.53) | TK2PYGM | |
| SCHEMBL27093412 | 0.89 | TK2 (0.49) | TK2PYGM | |
| SCHEMBL27093309 | 0.89 | TK2 (0.48) | TK2P2RY2PYGM | |
| SCHEMBL27094653 | 0.88 | TK2 (0.48) | TK2P2RY2 | |
| SCHEMBL19834965 | 0.87 | TK2 (0.45) | TK2 | |
| SCHEMBL27094652 | 0.87 | TK2 (0.46) | TK2P2RY2PYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112961860-A | Aptamers that bind to IL-6 and their use in treating or diagnosing IL-6 mediated disorders | 私募蛋白质体公司 | 2021-06-15 | — | — | CN | claimed |
| EP-3044334-B1 | PDGF AND VEGF APTAMERS HAVING IMPROVED STABILITY AND THEIR USE IN TREATING PDGF AND VEGF MEDIATED DISEASES AND DISORDERS | SOMALOGIC INC (US) | 2020-08-12 | — | — | EP | claimed |
| CN-110643610-A | Nucleic acid compounds for binding complement component 3 proteins | 私募蛋白质体公司 | 2020-01-03 | — | — | CN | claimed |
| EP-3224361-B1 | NUCLEIC ACID COMPOUNDS FOR BINDING GROWTH DIFFERENTIATION FACTOR 11 | SOMALOGIC INC (US) | 2019-06-19 | — | — | EP | claimed |
| EP-3149173-B1 | NUCLEIC ACID COMPOUNDS FOR BINDING TO COMPLEMENT COMPONENT 3 PROTEIN | SOMALOGIC INC (US) | 2018-02-07 | — | — | EP | claimed |
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SOMALOGIC OPERATING CO., INC. (US) | 2024-07-04 | — | — | US | disclosed |
| CN-109439664-B | Aptamer binding to IL-6 and use thereof in the treatment or diagnosis of IL-6 mediated disorders | 私募蛋白质体操作有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4323374-A1 | MODIFIED NUCLEOSIDES | SomaLogic Operating Co., Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-112961860-A | Aptamers that bind to IL-6 and their use in treating or diagnosing IL-6 mediated disorders | 私募蛋白质体公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-106459979-B | Nucleic acid compounds for binding complement component 3 proteins | 私募蛋白质体公司 | 2020-07-21 | — | — | CN | disclosed |
| CN-110643610-A | Nucleic acid compounds for binding complement component 3 proteins | 私募蛋白质体公司 | 2020-01-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218374-A1 | Nucleic Acid Compounds That Bind Coronavirus Proteins | SARS1, RNGTT, PABPC1 | TK2 3270/4885P2RY2 4661/4885PYGM 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.